Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-117 for prevention of delayed graft function in deceased donor kidney transplant recipients (Varvara)
2022-503091-89-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in delayed graft function (DGF) comparing EMPASIPRUBART (ARGX-117) with Placebo (2 arms). Primary endpoint: Primary endpoint: eGFR at 24 weeks posttransplant. Planned start Oct 2023; status: authorised.
02
Drugs
empasiprubart
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2022-503091-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503091-89-00.